Journal of International Oncology ›› 2019, Vol. 46 ›› Issue (10): 620-623.doi: 10.3760/cma.j.issn.1673-422X.2019.10.011

Previous Articles     Next Articles

lncRNA and small cell lung cancer

Ming Chao1, He Rui1, Sun Yuan1, Tian Linghan2, Zhao Guangqiang1   

  1. 1First Department of Thoracic Surgery, Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming 650100, China; 2Cancer Research Institute, Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer HospitalKunming 650100, China 

  • Online:2019-10-08 Published:2019-12-22
  • Contact: Zhao Guangqiang, Email: zgqst2012@163.com E-mail: zgqst2012@163.com
  • Supported by:

    National Natural Science Foundation of China (81702274); Health Science and Technology Plan Project of Yunnan Province of China (2018NS0071); Health and Family Planning Commission Medical Discipline Leadership Program of Yunnan Province of China (D-2017012); Technology Plan Project of Yunnan Province of China 2017FE467(-074)

Abstract:

The incidence and mortality of lung cancer rank first, and small cell lung cancer (SCLC) accounts for about 15% of lung cancer cases. In recent years, it has been found that long non-coding RNA (lncRNA) (TUG1, CCAT2, PVT1, HOTTIP and HOTAIR) plays a significant role in the development of SCLC. lncRNA can regulate the expression of related genes at the transcriptional, posttranscriptional and epigenetic levels, and it can infulence proliferation, invasion, metastasis and chemotherapy resistance of SCLC. 

Key words:

Small cell lung carcinoma, RNA, long noncoding